Van Diest Capital LLC Acquires New Shares in Elevance Health, Inc. $ELV

Van Diest Capital LLC bought a new stake in Elevance Health, Inc. (NYSE:ELV) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,349 shares of the company’s stock, valued at approximately $473,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ELV. Rossby Financial LCC increased its holdings in shares of Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Elevance Health during the 4th quarter valued at about $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health during the 4th quarter valued at about $32,000. ORG Partners LLC grew its position in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

ELV opened at $388.77 on Friday. The company has a market capitalization of $84.43 billion, a price-to-earnings ratio of 16.54, a price-to-earnings-growth ratio of 2.21 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $426.98. The business has a 50 day moving average price of $373.89 and a two-hundred day moving average price of $346.61.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same period last year, the firm earned $11.97 EPS. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts predict that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health’s payout ratio is 29.26%.

Analyst Ratings Changes

ELV has been the subject of several analyst reports. Mizuho boosted their price objective on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Sanford C. Bernstein lifted their target price on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday, April 24th. UBS Group lifted their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Citigroup upgraded Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Finally, Evercore reissued a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $416.11.

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.